Ensio Norjavaara
Research Subjects
Research Interests
Ensio Norjavaara has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Gunnar Selstam
10 shared publicationsSten Rosberg
6 shared publicationsCarina Ankarberg-Lindgren
Göteborg Pediatric Growth Research Center, Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
5 shared publications- Carina Ankarberg-Lindgren
Göteborg Pediatric Growth Research Center, Department of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, S-41685 Göteborg, Sweden
5 shared publications - Claes Ohlsson
University of Gothenburg
5 shared publications G. Selstam
5 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (5) , 425-431
Puberty promoting low dose testosterone treatment improved wellbeing and emotional state in boys with self-limited delayed puberty
Objectives: To evaluate changes in health-related quality of life in boys aged 14–16 years with delayed or slowly progressing puberty before and after low-dose testosterone treatment. Delayed puberty can cause short stature, emotional distress, and social challenges. Testosterone therapy promotes growth and masculinization, but its impact on quality of life remains poorly understood. Few studies have assessed psychosocial outcomes using validated instruments. Methods: Twenty-seven boys enrolled in the Pubertal Replacement in Boys Study and were randomized to testosterone enanthate (75 mg/month for 6 months; n=12) (n=12) or testosterone undecanoate (n=12) (250 mg every 3 months; n=15). Standardized self-report questionnaires assessed generic quality of life (primary outcome), stature-specific quality of life, depressive symptoms, and enjoyment of physical activity. Assessments were conducted at baseline, 6 months, and 12 months. Results: Twenty-six boys completed the study. Both regimens induced pubertal progression and a mean growth of 9.3 cm 12 months after start of replacement treatment. Significant improvements were observed in generic quality of life and depressive symptoms, with early gains sustained through 12 months. No changes were detected in stature-specific quality of life or enjoyment of physical activity. No statistical differences were found between treatment groups at 6 or 12 months. Exploratory analyses suggested that baseline testosterone serum levels were modestly associated with changes in social functioning, whereas later serum levels showed no such relationship. Conclusions: Low-dose testosterone therapy improves generic quality of life and mood in boys with self-limited delayed puberty, likely reflecting successful pubertal progression. These findings highlight the importance of psychosocial outcomes as indicators of treatment success, beyond growth acceleration, and support structured follow-up to address the emotional needs of adolescents with delayed puberty.
- 16 March 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (5) , 425-431
Open AccessPuberty promoting low dose testosterone treatment improved wellbeing and emotional state in boys with self-limited delayed puberty
Objectives: To evaluate changes in health-related quality of life in boys aged 14–16 years with delayed or slowly progressing puberty before and after low-dose testosterone treatment. Delayed puberty can cause short stature, emotional distress, and social challenges. Testosterone therapy promotes growth and masculinization, but its impact on quality of life remains poorly understood. Few studies have assessed psychosocial outcomes using validated instruments. Methods: Twenty-seven boys enrolled in the Pubertal Replacement in Boys Study and were randomized to testosterone enanthate (75 mg/month for 6 months; n=12) (n=12) or testosterone undecanoate (n=12) (250 mg every 3 months; n=15). Standardized self-report questionnaires assessed generic quality of life (primary outcome), stature-specific quality of life, depressive symptoms, and enjoyment of physical activity. Assessments were conducted at baseline, 6 months, and 12 months. Results: Twenty-six boys completed the study. Both regimens induced pubertal progression and a mean growth of 9.3 cm 12 months after start of replacement treatment. Significant improvements were observed in generic quality of life and depressive symptoms, with early gains sustained through 12 months. No changes were detected in stature-specific quality of life or enjoyment of physical activity. No statistical differences were found between treatment groups at 6 or 12 months. Exploratory analyses suggested that baseline testosterone serum levels were modestly associated with changes in social functioning, whereas later serum levels showed no such relationship. Conclusions: Low-dose testosterone therapy improves generic quality of life and mood in boys with self-limited delayed puberty, likely reflecting successful pubertal progression. These findings highlight the importance of psychosocial outcomes as indicators of treatment success, beyond growth acceleration, and support structured follow-up to address the emotional needs of adolescents with delayed puberty.
- 3 July 2014
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (11) , 1096-1101
Effect of exogenously administered glucagon versus spontaneous endogenous counter‐regulation on glycaemic recovery from insulin‐induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656 , and metformin
Aims: To study the effect of exogenous i.m. glucagon on recovery from controlled insulin‐induced hypoglycaemia in patients with type 2 diabetes treated with the novel glucokinase activator AZD1656 , in combination with metformin. Methods: This was a single‐centre randomized, open, two‐way crossover phase I, automated glucose clamp (Biostator ® ; Life Science Instruments, Elkhart, MD, USA) study ( NCT00817271 ) in eight patients (seven men and one woman, mean age 58.6 years, body mass index 28.1 kg/m 2 ). All patients received a stable dose of metformin twice daily, ranging from 1000 to 2250 mg. A 2‐day titration phase commenced with 40 mg AZD1656 twice daily, escalating to 80 mg twice daily if tolerated. This was followed by a single dose of 80 or 160 mg AZD1656 , administered on days 5 and 8 when metabolic studies were performed. After an overnight fast on days 5 and 8, controlled hypoglycaemia was induced using an exogenous i.v. infusion of insulin. Plasma glucose was lowered in a stepwise fashion over 3 h to attain a target nadir of 2.7 mmol/l. This was sustained for 30 min, at the end of which the hypoglycaemic clamp was released. In random sequence, patients either received an i.m. injection of 1 mg glucagon or were allowed to recover from hypoglycaemia by endogenous counter‐regulation. To avoid prolonged hypoglycaemia, a reverse glucose clamp was applied from 4 to 6 h post‐dose. Results: Three patients received 40 mg AZD1656 twice daily and five patients 80 mg twice daily. Mean plasma glucose at 20 min after release of the hypoglycaemic clamp was significantly lower (3.1 ± 0.3 mmol/l) for AZD1656 alone than for AZD1656 + glucagon (4.9 ± 0.8 mmol/l; p < 0.001 between the groups). Catecholamine and cortisol responses were similar on the AZD1656 + glucagon and AZD alone study days. Growth hormone response was 18% lower for AZD1656 alone (p = 0.01), consistent with the effect of a pharmacological dose of glucagon on growth hormone secretion. No safety or tolerability concerns were observed during treatment with AZ1656 . Conclusions: Exogenous glucagon was effective as a rescue treatment for hypoglycaemia induced during treatment with AZD1656 , given in combination with metformin in patients with type 2 diabetes.
- 3 July 2014
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (11) , 1096-1101
Effect of exogenously administered glucagon versus spontaneous endogenous counter‐regulation on glycaemic recovery from insulin‐induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656 , and metformin
Aims: To study the effect of exogenous i.m. glucagon on recovery from controlled insulin‐induced hypoglycaemia in patients with type 2 diabetes treated with the novel glucokinase activator AZD1656 , in combination with metformin. Methods: This was a single‐centre randomized, open, two‐way crossover phase I, automated glucose clamp (Biostator ® ; Life Science Instruments, Elkhart, MD, USA) study ( NCT00817271 ) in eight patients (seven men and one woman, mean age 58.6 years, body mass index 28.1 kg/m 2 ). All patients received a stable dose of metformin twice daily, ranging from 1000 to 2250 mg. A 2‐day titration phase commenced with 40 mg AZD1656 twice daily, escalating to 80 mg twice daily if tolerated. This was followed by a single dose of 80 or 160 mg AZD1656 , administered on days 5 and 8 when metabolic studies were performed. After an overnight fast on days 5 and 8, controlled hypoglycaemia was induced using an exogenous i.v. infusion of insulin. Plasma glucose was lowered in a stepwise fashion over 3 h to attain a target nadir of 2.7 mmol/l. This was sustained for 30 min, at the end of which the hypoglycaemic clamp was released. In random sequence, patients either received an i.m. injection of 1 mg glucagon or were allowed to recover from hypoglycaemia by endogenous counter‐regulation. To avoid prolonged hypoglycaemia, a reverse glucose clamp was applied from 4 to 6 h post‐dose. Results: Three patients received 40 mg AZD1656 twice daily and five patients 80 mg twice daily. Mean plasma glucose at 20 min after release of the hypoglycaemic clamp was significantly lower (3.1 ± 0.3 mmol/l) for AZD1656 alone than for AZD1656 + glucagon (4.9 ± 0.8 mmol/l; p < 0.001 between the groups). Catecholamine and cortisol responses were similar on the AZD1656 + glucagon and AZD alone study days. Growth hormone response was 18% lower for AZD1656 alone (p = 0.01), consistent with the effect of a pharmacological dose of glucagon on growth hormone secretion. No safety or tolerability concerns were observed during treatment with AZ1656 . Conclusions: Exogenous glucagon was effective as a rescue treatment for hypoglycaemia induced during treatment with AZD1656 , given in combination with metformin in patients with type 2 diabetes.
- Open Access
- 4 February 2014
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 81 (4) , 239-244
Physiological Estrogen Replacement Therapy for Puberty Induction in Girls: A Clinical Observational Study
Background/Aim: The goal of estrogen replacement therapy (ERT) in girls with hypogonadism is to achieve the endocrine milieu similar to natural puberty, where transdermal administration is the most physiological route. The aim of the study was to evaluate guidelines for the induction of puberty with transdermal estradiol (E2) patches in a large outpatient setting. Methods: In a retrospective study, serum E2 levels from 18 clinics were analyzed at the Göteborg Pediatric Growth Research Center laboratory, as part of the initiation of ERT in girls with hypogonadism. Exclusion criteria were pubertas tarda and pubertal arrest. Eighty-eight observations (50 with Turner syndrome, TS) were included. Serum E2 levels were determined by extraction + radioimmunoassay (detection limit 4 pmol/l) and analyzed in relation to the dose of Evorel® (25 µg/24 h, containing 1.60 mg estradiol hemihydrate; Janssen-Cilag Pharmaceutica N.V., Beerse, Belgium). Results: There was a linear relationship between serum E2 and the weight-based dose, with r = 0.56, p < 0.0001 for all observations and r = 0.59, p < 0.0001 for the TS study group. Linear regression analysis for doses of 0.05-0.07 µg/kg resulted in serum levels of 17-23 pmol/l (TS 17-24 pmol/l) and doses of 0.08-0.12 µg/kg in 26-39 pmol/l (TS 27-39 pmol/l). Conclusions: For the initiation of ERT with nocturnally administered E2 patches, we recommend reduced starting doses of 0.05-0.07 µg/kg, with the goal of mimicking E2 levels during gonadarche. In older girls, when breast development is of high priority, the starting dose can still be 0.08-0.12 µg/kg.
- 4 February 2014
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 81 (4) , 239-244
Open AccessPhysiological Estrogen Replacement Therapy for Puberty Induction in Girls: A Clinical Observational Study
Background/Aim: The goal of estrogen replacement therapy (ERT) in girls with hypogonadism is to achieve the endocrine milieu similar to natural puberty, where transdermal administration is the most physiological route. The aim of the study was to evaluate guidelines for the induction of puberty with transdermal estradiol (E2) patches in a large outpatient setting. Methods: In a retrospective study, serum E2 levels from 18 clinics were analyzed at the Göteborg Pediatric Growth Research Center laboratory, as part of the initiation of ERT in girls with hypogonadism. Exclusion criteria were pubertas tarda and pubertal arrest. Eighty-eight observations (50 with Turner syndrome, TS) were included. Serum E2 levels were determined by extraction + radioimmunoassay (detection limit 4 pmol/l) and analyzed in relation to the dose of Evorel® (25 µg/24 h, containing 1.60 mg estradiol hemihydrate; Janssen-Cilag Pharmaceutica N.V., Beerse, Belgium). Results: There was a linear relationship between serum E2 and the weight-based dose, with r = 0.56, p < 0.0001 for all observations and r = 0.59, p < 0.0001 for the TS study group. Linear regression analysis for doses of 0.05-0.07 µg/kg resulted in serum levels of 17-23 pmol/l (TS 17-24 pmol/l) and doses of 0.08-0.12 µg/kg in 26-39 pmol/l (TS 27-39 pmol/l). Conclusions: For the initiation of ERT with nocturnally administered E2 patches, we recommend reduced starting doses of 0.05-0.07 µg/kg, with the goal of mimicking E2 levels during gonadarche. In older girls, when breast development is of high priority, the starting dose can still be 0.08-0.12 µg/kg.
- 1 January 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 52 (1) , 15-26
Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test
Objective: Different hypothalamic-pituitary-adrenal (HPA) axis function tests are used for diagnosing disease and evaluating suppressive effects of corticosteroid treatment. Our objectives were to evaluate sensitivity and precision of different HPA axis tests to be able to select one that combines good performance with good practicability, suitable for investigation of new corticosteroids in clinical trials. Methods: In this descriptive, double-blind, parallel-group study, 60 healthy male volunteers were treated with once-daily morning doses of prednisolone for 2 weeks. The volunteers were randomized to 1 of 5 treatment groups (prednisolone 2.5, 5, 7.5, 10, or 15 mg). We compared the plasma-cortisol (p-cortisol) 24-hour average concentration (C,) with morning (08:00 hours) p-cortisol, daytime p-cortisol C,, and 24-hour urinary cortisol excretion. Adrenocorticotrophic hormone (ACTH) stimulation tests and the metyrapone test were also performed. Furthermore, we analyzed levels of serum dehydroepiandrosterone sulfate (s-DHEAS), insulin, and markers of bone turnover. Results: Dose-related effects were shown, but the magnitude of effects and sensitivities varied greatly between the tests. P-cortisol measurements over the course of 24 hours were used as the reference method. Low- and standard-dose ACTH tests and morning s-DHEAS levels had similar sensitivity. Urinary cortisol excretion and the metyrapone stimulation test had low sensitivity. The effects of prednisolone on markers of bone turnover were, in general, less than those on the HPA axis. Only osteocalcin, procollagen type 1 C-peptide and procollagen type 3 N-peptide were significantly affected. Treatment with prednisolone was well tolerated. Conclusion: Changes in s-DHEAS and the low-dose ACTH test combine good sensitivity and precision for evaluation of the suppressive effect of exogenous corticosteroids on the HPA axis, and they are easy to perform
- 1 January 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 52 (1) , 15-26
Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test
Objective: Different hypothalamic-pituitary-adrenal (HPA) axis function tests are used for diagnosing disease and evaluating suppressive effects of corticosteroid treatment. Our objectives were to evaluate sensitivity and precision of different HPA axis tests to be able to select one that combines good performance with good practicability, suitable for investigation of new corticosteroids in clinical trials. Methods: In this descriptive, double-blind, parallel-group study, 60 healthy male volunteers were treated with once-daily morning doses of prednisolone for 2 weeks. The volunteers were randomized to 1 of 5 treatment groups (prednisolone 2.5, 5, 7.5, 10, or 15 mg). We compared the plasma-cortisol (p-cortisol) 24-hour average concentration (C,) with morning (08:00 hours) p-cortisol, daytime p-cortisol C,, and 24-hour urinary cortisol excretion. Adrenocorticotrophic hormone (ACTH) stimulation tests and the metyrapone test were also performed. Furthermore, we analyzed levels of serum dehydroepiandrosterone sulfate (s-DHEAS), insulin, and markers of bone turnover. Results: Dose-related effects were shown, but the magnitude of effects and sensitivities varied greatly between the tests. P-cortisol measurements over the course of 24 hours were used as the reference method. Low- and standard-dose ACTH tests and morning s-DHEAS levels had similar sensitivity. Urinary cortisol excretion and the metyrapone stimulation test had low sensitivity. The effects of prednisolone on markers of bone turnover were, in general, less than those on the HPA axis. Only osteocalcin, procollagen type 1 C-peptide and procollagen type 3 N-peptide were significantly affected. Treatment with prednisolone was well tolerated. Conclusion: Changes in s-DHEAS and the low-dose ACTH test combine good sensitivity and precision for evaluation of the suppressive effect of exogenous corticosteroids on the HPA axis, and they are easy to perform
- Open Access
- 27 August 2013
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 80 (2) , 100-110
Pubertal Growth and Serum Testosterone and Estradiol Levels in Boys
Background/Aims: To study serum testosterone and estradiol in healthy boys in relation to growth during puberty up to peak height velocity (PHV). Methods: Growth velocity was analyzed through testosterone (n = 41) and 17β-estradiol (n = 37) 24-hour profiles in a dose-response model. Participants were 26 healthy boys admitted for short or tall stature or participating as healthy volunteers at the Queen Silvia Children's Hospital. Other inclusion criteria included the following: gestational age 37-42 weeks, birth weight and length >-2 standard deviation score (SDS) and prepubertal height and weight within ±3 SDS. Testosterone was measured using a modified radioimmunoassay (RIA) with a detection limit of 0.03 nmol/l. Estradiol was determined using an ultrasensitive extraction RIA with a detection limit 4 pmol/l. A sixth-grade polynomial was fitted to each child's growth data, giving growth velocity and age at PHV. Results: Growth velocity increased by 50% from prepubertal growth to PHV at a morning testosterone level of 3.1 nmol/l (95% confidence interval 2.4-4.2), EC50. The corresponding EC50 of 17β-estradiol was 6.5 pmol/l (3.2-13). Boys approaching PHV (10 nmol/l and 17β-estradiol >9 pmol/l. Conclusion: Observed early puberty/initial mid puberty morning testosterone levels of 2.4-4.2 nmol/l are associated with a 50% increase in growth velocity from prepubertal growth to PHV in healthy boys.
- 27 August 2013
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 80 (2) , 100-110
Open AccessPubertal Growth and Serum Testosterone and Estradiol Levels in Boys
Background/Aims: To study serum testosterone and estradiol in healthy boys in relation to growth during puberty up to peak height velocity (PHV). Methods: Growth velocity was analyzed through testosterone (n = 41) and 17β-estradiol (n = 37) 24-hour profiles in a dose-response model. Participants were 26 healthy boys admitted for short or tall stature or participating as healthy volunteers at the Queen Silvia Children's Hospital. Other inclusion criteria included the following: gestational age 37-42 weeks, birth weight and length >-2 standard deviation score (SDS) and prepubertal height and weight within ±3 SDS. Testosterone was measured using a modified radioimmunoassay (RIA) with a detection limit of 0.03 nmol/l. Estradiol was determined using an ultrasensitive extraction RIA with a detection limit 4 pmol/l. A sixth-grade polynomial was fitted to each child's growth data, giving growth velocity and age at PHV. Results: Growth velocity increased by 50% from prepubertal growth to PHV at a morning testosterone level of 3.1 nmol/l (95% confidence interval 2.4-4.2), EC50. The corresponding EC50 of 17β-estradiol was 6.5 pmol/l (3.2-13). Boys approaching PHV (10 nmol/l and 17β-estradiol >9 pmol/l. Conclusion: Observed early puberty/initial mid puberty morning testosterone levels of 2.4-4.2 nmol/l are associated with a 50% increase in growth velocity from prepubertal growth to PHV in healthy boys.
- 1 December 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 98 (3) , 436-444
The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food
- 1 December 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 98 (3) , 436-444
The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food
- Open Access
- 14 November 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e49404
Age at Adiposity Rebound Is Associated with Fat Mass in Young Adult Males—The GOOD Study
Age at adiposity rebound (AR) is associated with obesity and Type 2 Diabetes in adults. The aim of the present study was to investigate the role of age at AR in adult fat mass, fat distribution and pubertal timing for a Swedish cohort. This is a retrospective cohort study. Detailed growth charts were retrieved for the men participating in the population-based GOOD (Gothenburg Osteoporosis and Obesity Determinants) study (n = 573). Body composition was analysed using dual X-ray absorptiometry and computed tomography at 18–20 years of age. Age and BMI at AR were calculated using pediatric growth charts and AR was defined as the lowest BMI between 3 and 9 years of age. Subjects were divided into early (age at AR below 5.4 years of age), middle (age at AR 5.4 to 6.8 years of age) and late (age at AR after 6.8 years of age) age at AR tertiles. Subjects in the early age at AR tertile had higher young adult BMI (+8%), whole body fat mass (+34%) and amount of subcutaneous adipose tissue (+61%) than the subjects in the middle and late tertiles (p<0.01). The early age at AR tertile had an increased risk of obesity (Odds Ratio 4.1 [95% CI 1.2–13.9]) compared with the middle and late tertiles. In addition, the early age at AR tertile had Peak Height Velocity (PHV) 7 months earlier than the late tertile. Early age at AR was associated with young adult obesity as a consequence of a high amount of subcutaneous adipose tissue in men. In addition we made the novel observation that early age at AR was associated with an early puberty in men.
- 14 November 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e49404
Open AccessAge at Adiposity Rebound Is Associated with Fat Mass in Young Adult Males—The GOOD Study
Age at adiposity rebound (AR) is associated with obesity and Type 2 Diabetes in adults. The aim of the present study was to investigate the role of age at AR in adult fat mass, fat distribution and pubertal timing for a Swedish cohort. This is a retrospective cohort study. Detailed growth charts were retrieved for the men participating in the population-based GOOD (Gothenburg Osteoporosis and Obesity Determinants) study (n = 573). Body composition was analysed using dual X-ray absorptiometry and computed tomography at 18–20 years of age. Age and BMI at AR were calculated using pediatric growth charts and AR was defined as the lowest BMI between 3 and 9 years of age. Subjects were divided into early (age at AR below 5.4 years of age), middle (age at AR 5.4 to 6.8 years of age) and late (age at AR after 6.8 years of age) age at AR tertiles. Subjects in the early age at AR tertile had higher young adult BMI (+8%), whole body fat mass (+34%) and amount of subcutaneous adipose tissue (+61%) than the subjects in the middle and late tertiles (p<0.01). The early age at AR tertile had an increased risk of obesity (Odds Ratio 4.1 [95% CI 1.2–13.9]) compared with the middle and late tertiles. In addition, the early age at AR tertile had Peak Height Velocity (PHV) 7 months earlier than the late tertile. Early age at AR was associated with young adult obesity as a consequence of a high amount of subcutaneous adipose tissue in men. In addition we made the novel observation that early age at AR was associated with an early puberty in men.
- 1 November 2012
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 50 (11) , 765-777
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp
AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both the pancreas and the liver, and with the potential to deliver effective glucose-lowering in Type 2 diabetes mellitus. Here, we present the tolerability, pharmacokinetics and pharmacodynamics of AZD1656 in two single-blind, randomized, placebo-controlled studies, one with Western and the other with Japanese healthy adult male subjects. Both studies evaluated oral single ascending doses of AZD1656 of up to 180 mg, administered during euglycemic clamp conditions to explore a wide dose range without risking hypoglycemia. Safety, pharmacokinetics and effects on serum insulin and glucose infusion rate were assessed. A population pharmacokinetics analysis was also conducted. AZD1656 was well tolerated in single doses up to 180 mg in both populations. AZD1656 was rapidly absorbed, and a dose-proportional increase in total exposure was observed for AZD1656 and the equipotent metabolite, AZD5658. Taking differences in body weight into account, there were no differences in pharmacokinetic parameters between Western and Japanese subjects. A dose-dependent blood glucose lowering effect was indirectly demonstrated by the increased glucose infusion rate required to maintain euglycemia, which was of similar magnitude in both populations. Dose-dependent increases in insulin secretion were also observed. No safety concerns were raised. AZD1656 displayed uncomplicated pharmacokinetics and dose-dependent pharmacodynamics effects were observed. The results suggest no ethnic differences in AZD1656 tolerability, pharmacokinetics or pharmacodynamics.
- 1 November 2012
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 50 (11) , 765-777
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp
AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both the pancreas and the liver, and with the potential to deliver effective glucose-lowering in Type 2 diabetes mellitus. Here, we present the tolerability, pharmacokinetics and pharmacodynamics of AZD1656 in two single-blind, randomized, placebo-controlled studies, one with Western and the other with Japanese healthy adult male subjects. Both studies evaluated oral single ascending doses of AZD1656 of up to 180 mg, administered during euglycemic clamp conditions to explore a wide dose range without risking hypoglycemia. Safety, pharmacokinetics and effects on serum insulin and glucose infusion rate were assessed. A population pharmacokinetics analysis was also conducted. AZD1656 was well tolerated in single doses up to 180 mg in both populations. AZD1656 was rapidly absorbed, and a dose-proportional increase in total exposure was observed for AZD1656 and the equipotent metabolite, AZD5658. Taking differences in body weight into account, there were no differences in pharmacokinetic parameters between Western and Japanese subjects. A dose-dependent blood glucose lowering effect was indirectly demonstrated by the increased glucose infusion rate required to maintain euglycemia, which was of similar magnitude in both populations. Dose-dependent increases in insulin secretion were also observed. No safety concerns were raised. AZD1656 displayed uncomplicated pharmacokinetics and dose-dependent pharmacodynamics effects were observed. The results suggest no ethnic differences in AZD1656 tolerability, pharmacokinetics or pharmacodynamics.
- 1 November 2012
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 55 (5) , 511-518
Longitudinal Assessment of Bone Mineral Density in Children and Adolescents With Inflammatory Bowel Disease
Objectives: Low bone mineral density (BMD) is recognized as a potential problem in children with inflammatory bowel disease (IBD). We aimed to describe the longitudinal development of BMD in a population of Swedish pediatric patients with IBD.Methods: A total of 144 patients with IBD (93 males; 83 with ulcerative colitis [UC], 45 with Crohn disease [CD]) were examined with dual‐energy x‐ray absorptiometry at baseline. At follow‐up 2 years later, 126 of the initial 144 patients were reexamined. BMD values are expressed as z scores.Results: Children with UC and CD had significantly lower mean BMD z scores for the lumbar spine (LS) at baseline and after 2 years. The reduction in BMD was equally pronounced in patients with UC and CD, and neither group improved their z score during the follow‐up period. Furthermore, significantly lower mean BMD z scores for the LS were found at baseline in boys (−1.1 SD, ±2.7 SD, P < 0.001), but not in girls (−0.0 SD, ±3.0 SD). This finding remained unchanged at follow‐up. Subanalyses of the different age groups at baseline showed the lowest BMD values in the group of patients ages 17 to 19 years in boys (mean z score for the LS 1.59 SD, ±3.1 SD) and in girls (mean z score for the LS −3.40 SD, ±3.1 SD); however, at follow‐up, these patients had improved their BMD significantly (mean change z score for the LS 1.00 SD, 95% CI 0.40–1.60; 1.90 SD, 95% CI 0.60–3.20).Conclusions: In this longitudinal study, the entire group of pediatric patients with IBD showed permanent decreases in their BMD z scores for the LS; however, our data indicate that afflicted children have the potential to improve their BMD by the time they reach early adulthood.
- 1 November 2012
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 55 (5) , 511-518
Longitudinal Assessment of Bone Mineral Density in Children and Adolescents With Inflammatory Bowel Disease
Objectives: Low bone mineral density (BMD) is recognized as a potential problem in children with inflammatory bowel disease (IBD). We aimed to describe the longitudinal development of BMD in a population of Swedish pediatric patients with IBD.Methods: A total of 144 patients with IBD (93 males; 83 with ulcerative colitis [UC], 45 with Crohn disease [CD]) were examined with dual‐energy x‐ray absorptiometry at baseline. At follow‐up 2 years later, 126 of the initial 144 patients were reexamined. BMD values are expressed as z scores.Results: Children with UC and CD had significantly lower mean BMD z scores for the lumbar spine (LS) at baseline and after 2 years. The reduction in BMD was equally pronounced in patients with UC and CD, and neither group improved their z score during the follow‐up period. Furthermore, significantly lower mean BMD z scores for the LS were found at baseline in boys (−1.1 SD, ±2.7 SD, P < 0.001), but not in girls (−0.0 SD, ±3.0 SD). This finding remained unchanged at follow‐up. Subanalyses of the different age groups at baseline showed the lowest BMD values in the group of patients ages 17 to 19 years in boys (mean z score for the LS 1.59 SD, ±3.1 SD) and in girls (mean z score for the LS −3.40 SD, ±3.1 SD); however, at follow‐up, these patients had improved their BMD significantly (mean change z score for the LS 1.00 SD, 95% CI 0.40–1.60; 1.90 SD, 95% CI 0.60–3.20).Conclusions: In this longitudinal study, the entire group of pediatric patients with IBD showed permanent decreases in their BMD z scores for the LS; however, our data indicate that afflicted children have the potential to improve their BMD by the time they reach early adulthood.
- 17 October 2012
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 78 (4) , 218-225
Estradiol and Pubertal Growth in Girls
Aim: The objective of this study was to determine estradiol levels and assess their relationship to pubertal growth in girls. Methods: Thirty-seven 24-hour profiles of serum 17β-estradiol were retrospectively analyzed in relation to growth in 27 healthy girls admitted for short/tall stature (n = 20) or recruited as healthy volunteers at Göteborg Pediatric Growth Research Center (GP-GRC). Inclusion Criteria: Birth weight and length above –2 SDS, gestational age 37–42 weeks, prepubertal height and weight within ±3 SDS and normal growth hormone secretion. Serum estradiol was determined by a validated ultrasensitive extraction radioimmunoassay (detection limit 4 pmol/l). A sixth-grade polynomial was fitted to each girl’s growth data. Growth velocity and age at peak height velocity (PHV) was calculated. Results: A dose-response model was used to find the morning 17β-estradiol level at which half of the maximal pubertal growth up to PHV had occurred, EC50, which was 20 pmol/l with a 95% confidence interval of 13–31. When 17β-estradiol exceeds early pubertal levels (Tanner breast stage 2, 10–51 pmol/l), less than 25% of the potential pubertal growth velocity up to PHV remains. Conclusions: Morning 17β-estradiol in the low early pubertal range (13–31 pmol/l) is associated with increasing growth velocity.
- 17 October 2012
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 78 (4) , 218-225
Estradiol and Pubertal Growth in Girls
Aim: The objective of this study was to determine estradiol levels and assess their relationship to pubertal growth in girls. Methods: Thirty-seven 24-hour profiles of serum 17β-estradiol were retrospectively analyzed in relation to growth in 27 healthy girls admitted for short/tall stature (n = 20) or recruited as healthy volunteers at Göteborg Pediatric Growth Research Center (GP-GRC). Inclusion Criteria: Birth weight and length above –2 SDS, gestational age 37–42 weeks, prepubertal height and weight within ±3 SDS and normal growth hormone secretion. Serum estradiol was determined by a validated ultrasensitive extraction radioimmunoassay (detection limit 4 pmol/l). A sixth-grade polynomial was fitted to each girl’s growth data. Growth velocity and age at peak height velocity (PHV) was calculated. Results: A dose-response model was used to find the morning 17β-estradiol level at which half of the maximal pubertal growth up to PHV had occurred, EC50, which was 20 pmol/l with a 95% confidence interval of 13–31. When 17β-estradiol exceeds early pubertal levels (Tanner breast stage 2, 10–51 pmol/l), less than 25% of the potential pubertal growth velocity up to PHV remains. Conclusions: Morning 17β-estradiol in the low early pubertal range (13–31 pmol/l) is associated with increasing growth velocity.